| 1 |
32202086 | Novel Emerging Therapies for Erectile Dysfunction. | 2021 Jan |
1 |
| 2 |
32526061 | Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. | 2021 Jan |
2 |
| 3 |
32744956 | Sildenafil in Combination Therapy against Cancer: A Literature Review. | 2021 |
2 |
| 4 |
33348311 | Phosphodiesterase 5 (PDE5): Structure-function regulation and therapeutic applications of inhibitors. | 2021 Feb |
2 |
| 5 |
33596129 | Disease-specific platelet signaling defects in idiopathic pulmonary arterial hypertension. | 2021 May 1 |
2 |
| 6 |
33670094 | Structural Determination, Biological Function, and Molecular Modelling Studies of Sulfoaildenafil Adulterated in Herbal Dietary Supplement. | 2021 Feb 11 |
2 |
| 7 |
33718200 | New Approaches in Oncology for Repositioning Drugs: The Case of PDE5 Inhibitor Sildenafil. | 2021 |
1 |
| 8 |
34369112 | Switching Reactive Oxygen Species into Reactive Nitrogen Species by Photocleaved O2 -Released Nanoplatforms Favors Hypoxic Tumor Repression. | 2021 Oct |
1 |
| 9 |
34471575 | Is Tadalafil an Effective Treatment Option for Interstitial Cystitis/Painful Bladder Syndrome? A Report of a Challenging Case. | 2021 Jul |
2 |
| 10 |
34471776 | On the Viability of Tadalafil-Based 18F-Radiotracers for In Vivo Phosphodiesterase 5 (PDE5) PET Imaging. | 2021 Aug 24 |
2 |
| 11 |
32872119 | Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension. | 2020 Aug 28 |
1 |
| 12 |
33115566 | TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds. | 2020 Oct 28 |
1 |
| 13 |
31110491 | Androgen Deficiency and Phosphodiesterase Type 5 Expression Changes in Aging Male: Therapeutic Implications. | 2019 |
1 |
| 14 |
31339910 | The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis. | 2019 |
2 |
| 15 |
31409013 | Intervening with the Nitric Oxide Pathway to Alleviate Pulmonary Hypertension in Pulmonary Vein Stenosis. | 2019 Aug 12 |
1 |
| 16 |
29687019 | Phosphodiesterase-5 inhibition potentiates cerebrovascular reactivity in chronic traumatic brain injury. | 2018 Apr |
2 |
| 17 |
30701875 | Modern view on the place of riociguat in the treatment of pulmonary hypertension. | 2018 Apr 19 |
1 |
| 18 |
27903966 | PDE5 inhibitors enhance the lethality of pemetrexed through inhibition of multiple chaperone proteins and via the actions of cyclic GMP and nitric oxide. | 2017 Jan 3 |
3 |
| 19 |
28379598 | Sildenafil-associated hepatoxicity: a review of the literature. | 2017 Mar |
1 |
| 20 |
28964803 | Cyclic guanosine monophosphate modulates accumulation of phosphodiesterase 5 inhibitors in human platelets. | 2017 Dec 1 |
2 |
| 21 |
26530829 | Mechanisms underlying spontaneous constrictions of postcapillary venules in the rat stomach. | 2016 Feb |
1 |
| 22 |
26620458 | Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update. | 2016 Sep-Oct |
1 |
| 23 |
27419107 | Let's rethinking about the safety of phosphodiesterase type 5 inhibitor in the patients with erectile dysfunction after radical prostatectomy. | 2016 Jun |
1 |
| 24 |
27872007 | The Role of PDE5 Inhibitors and the NO/cGMP Pathway in Cancer. | 2016 Jan |
2 |
| 25 |
25799991 | Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. | 2015 Mar 26 |
3 |
| 26 |
26027619 | PDE 5 inhibition with udenafil improves left ventricular systolic/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction; A 12-week, randomized, double-blind, placebo-controlled trial. | 2015 Jun |
1 |
| 27 |
26047999 | [Phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension]. | 2015 Jul-Sep |
1 |
| 28 |
26093192 | S-nitrosylation of PDE5 increases its ubiquitin-proteasomal degradation. | 2015 Sep |
1 |
| 29 |
26138471 | Emerging drugs for preeclampsia--the endothelium as a target. | 2015 |
1 |
| 30 |
26205960 | Cyclic GMP in Vascular Relaxation: Export Is of Similar Importance as Degradation. | 2015 Sep |
1 |
| 31 |
24341639 | Identification of PDE5A:E90K: a polymorphism in the canine phosphodiesterase 5A gene affecting basal cGMP concentrations of healthy dogs. | 2014 Jan-Feb |
1 |
| 32 |
24877179 | Nebivolol potentiates the efficacy of PDE5 inhibitors to relax corpus cavernosum and penile arteries from diabetic patients by enhancing the NO/cGMP pathway. | 2014 May |
1 |
| 33 |
25051133 | Therapeutic potentials of phosphodiesterase-5 inhibitors in cardiovascular disease. | 2014 |
1 |
| 34 |
23018163 | The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia. | 2013 Mar |
1 |
| 35 |
23382484 | Phosphodiesterase type 5 inhibition improves arterial stiffness after exercise but not exercise capacity in hypertensive men. | 2013 Mar |
2 |
| 36 |
23421435 | Synergistic effects of BAY 60-4552 and vardenafil on relaxation of corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure. | 2013 May |
1 |
| 37 |
23475211 | Phosphodiesterase type 5 (PDE5) is co-localized with key proteins of the nitric oxide/cyclic GMP signaling in the human prostate. | 2013 Jun |
2 |
| 38 |
23917809 | Effectiveness and safety of phosphodiesterase 5 inhibitors in patients with cardiovascular disease and hypertension. | 2013 Oct |
3 |
| 39 |
24157969 | Increased PDE5 activity and decreased Rho kinase and PKC activities in colonic muscle from caveolin-1-/- mice impair the peristaltic reflex and propulsion. | 2013 Dec |
2 |
| 40 |
24432631 | [Cardiovascular-protective effect of tadalafil in the treatment of erectile dysfunction]. | 2013 Dec |
2 |
| 41 |
21950284 | Effect of vardenafil on nitric oxide synthase expression in the paraventricular nucleus of rats without sexual stimulation. | 2012 May |
2 |
| 42 |
22028410 | Testosterone regulates smooth muscle contractile pathways in the rat prostate: emphasis on PDE5 signaling. | 2012 Jan 15 |
1 |
| 43 |
22067410 | Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study. | 2012 Jan |
2 |
| 44 |
22248110 | Does current scientific and clinical evidence support the use of phosphodiesterase type 5 inhibitors for the treatment of premature ejaculation? a systematic review and meta-analysis. | 2012 Sep |
1 |
| 45 |
22948216 | Phosphodiesterase type 5 inhibition reverts prostate fibroblast-to-myofibroblast trans-differentiation. | 2012 Nov |
2 |
| 46 |
23086989 | Melatonin inhibits nitric oxide signaling by increasing PDE5 phosphorylation in coronary arteries. | 2012 Dec 15 |
1 |
| 47 |
21036891 | PDE5 inhibition with sildenafil improves left ventricular diastolic function, cardiac geometry, and clinical status in patients with stable systolic heart failure: results of a 1-year, prospective, randomized, placebo-controlled study. | 2011 Jan |
1 |
| 48 |
21269399 | Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings. | 2011 Apr |
1 |
| 49 |
21697861 | Expression and distribution of key enzymes of the cyclic GMP signaling in the human clitoris: relation to phosphodiesterase type 5 (PDE5). | 2011 Sep-Oct |
2 |
| 50 |
21702653 | Tadalafil for the treatment of pulmonary arterial hypertension. | 2011 Jun |
1 |